1 completed, 1 recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Digoxin (0.25mg): new trials by email Literature Review of Digoxin (0.25mg) trials Research Report on Digoxin (0.25mg)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates Evobrutinib (45mg), Digoxin (0.25mg), Metformin (10mg) - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 40 | 2021-10-04 | 2025-12-05 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
Leiomyosarcoma (1) · Sarcoma (1) · Sarcoma, Alveolar Soft Part (1) · Sarcoma, Synovial (1)
Advenchen Laboratories, LLC (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
China (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1) · United States (1)